Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Swiss pharmaceuticals giant Novartis posted Thursday a 29 percent increase in first-half net income, at $7.6 billion -- and ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. [Operator Instructions].

Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to an 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and ...

Though there were no historical benchmarks to gauge the response, the Dollar Index could fall more than 5%. Sterling edged higher versus the euro but remained weaker against a firmer dollar after the ...